Information  X 
Enter a valid email address

Faron Pharma OY Ord NPV (DI) (FARN)

Related News

20-Mar-2020 09:50 AM

Faron Pharmaceuticals narrows losses on lower R&D costs

Faron Pharmaceuticals narrowed annual pre-tax losses on lower research and development costs. For the year ended 31 December 2019, pre-tax losses narrowed to €13.3m from €20.1m on-year. The R&D costs decreased by €6.3m from €16.5m
13-Sep-2018 08:26 AM

Faron Pharmaceuticals losses nearly double as costs spiral

Faron Pharmaceuticals said Thursday first-half losses nearly doubled amid rising costs related to the end phase of a clinical trial for its respiratory treatment and an increase in development costs. For the six months ended 30 June 2018, the company re
19-Dec-2017 08:11 AM

INFORAAA trial gets recommendation from IDMC, says Faron

Faron Pharmaceuticals has received the first recommendation from the independent data monitoring committee of the INFORAAA study to continue the trial as planned using Faron's wholly owned lead product, Traumakine. The study currently has six ope
14-Dec-2017 07:39 AM

Faron to host R&D day in February

Faron Pharmaceuticals plans to host an R&D Day on 21 Feb at Panmure Gordon's offices, One New Change, London, EC4M 9AF. The event will provide an opportunity to hear about the company, its R&D strategy and pipeline developments, with a focus on Cl
11-Dec-2017 09:58 AM

Faron completes recruitment for Traumakine trial

Faron Pharmaceuticals has completed recruitment, on track, for its phase III INTEREST trial of Traumakine for the treatment of moderate to severe acute respiratory distress syndrome (ARDS). Thew company also said it has adopted recommendations from the I
01-Dec-2017 08:17 AM

Faron appoints chief commercial officer

Faron Pharmaceuticals has appointed Dr. Juhana Heinonen as chief commercial officer. Faron said Heinonen would join the company in January from AstraZeneca where he served as the global marketing director for AstraZeneca/Medimmune's Fasenra (benra
20-Nov-2017 09:44 AM

Faron appoints Nomad

Faron Pharmaceuticals has appointed Panmure Gordon (UK) as the company's nominated adviser, in addition to its existing appointment as broker, with immediate effect. At 9:44am: (LON:FARN) Faron Pharmaceuticals share price was 0p at 830p Story p
02-Oct-2017 09:46 AM

Faron's Traumakine gets PIM designation from MHRA

Faron's Traumakine has received promising innovative medicine (PIM) designation from the UK Medicines and Healthcare Products Regulatory Agency for the treatment of acute respiratory distress syndrome. Traumakine is currently undergoing phase I
07-Sep-2017 08:30 AM

Broker Forecast - Panmure Gordon issues a broker note on Faron Pharmaceuticals

Panmure Gordon today reaffirms its buy investment rating on Faron Pharmaceuticals (LON:FARN) and set its price target at 723p. Story provided by
06-Sep-2017 07:55 AM

Faron losses widen

Operating losses at Faron Pharmaceuticals rose to €7.2m in the six months to the end of June - up from €3.0m last time. Faron said that during the period it continued to maintain its focused and cost-conscious financial strategy, without comp
04-Sep-2017 07:41 AM

FDA advises Faron to proceed directly to BLA

Faron Pharmaceuticals said the FDA has proposed that the company can proceed directly to biologics licence application (BLA) submission pending positive results from the two on-going phase III trials (INTEREST in Europe and MR11A8-2 in Japan) with the com
04-Aug-2017 07:50 AM

Faron update on Traumakine study

Faron Pharmaceuticals has issued an update on the INTEREST phase III study treating patients with moderate to severe acute respiratory distress sndrome (ARDS) with its lead product Traumakine, following a meeting of the trial's independent data monit
16-May-2017 02:05 PM

All proposals passed at AGM of Faron

Faron Pharmaceuticals has confirmed that, at today's Annual General Meeting, all the proposals of the Board and its committees were approved. At 2:05pm: (LON:FARN) Faron Pharmaceuticals share price was -12.5p at 767.5p Story provided by StockM
08-May-2017 07:56 AM

Faron gets further study recommendation from IDMC

Faron Pharmaceuticals has been given another recommendation to continue the study for the treatment of patients with moderate to severe acute respiratory distress syndrome (ARDS) with its lead product Traumakine by the Independent Data Monitoring Committe
28-Apr-2017 08:44 AM

Faron warrants exercised

Faron Pharmaceuticals has received gross proceeds of €88,832.10 following the exercise of warrants over 38,430 ordinary shares at €1.55 apiece and 14,560 at €2.01 per share. At 8:44am: (LON:FARN) Faron Pharmaceuticals share price was +2.5
18-Apr-2017 09:15 AM

Faron collaboration with Birmingham University

Faron Pharmaceuticals has signed an agreement with the University of Birmingham Medical School to initiate a liver cancer programme testing Clevegen, the company's immuno switch antibody, in clinical trials. Faron said this collaboration would focu
29-Mar-2017 09:57 AM

Faron net losses rise

Faron Pharmaceuticals' net losses rose to €9.2m in the year to the end of December - up from €6.2m in 2015. The company's revenue was €1.2 million for the year ended 31 December 2016 (2015: €0.5m), which comprised of sale o
01-Mar-2017 01:59 PM

Faron raises £5m via placing, subscription

Faron Pharmaceuticals has confirmed that its has raised approximately £5m (before expenses) by way of the placing of 1,362,340 shares and the subscription of 60,000 subscription shares at the issue price of 350p apiece. The Company said: "The
20-Feb-2017 02:10 PM

Broker Forecast - Panmure Gordon issues a broker note on Faron Pharmaceuticals

Panmure Gordon today reaffirms its buy investment rating on Faron Pharmaceuticals (LON:FARN) and raised its price target to 404p (from 361p). Story provided by
09-Feb-2017 09:06 AM

Faron excited about prospects

Faron Pharmaceuticals' board is excited about the company's prospects for 2017 and beyond. Chief executive Dr Markku Jalkanen said: "We are getting close to read-out of the INTEREST trial, which we believe could revolutionise intensive car
31-Oct-2016 07:32 AM

Faron patent application accepted in Finland

Faron Pharmaceuticals has confirmed that its patent application to protect the intravenous use of interferon-beta (IFN-beta) in a novel formulation has been accepted by the Finnish patent office. The allowed claims cover single intravenous dose of IFN-b
14-Jun-2016 09:49 AM

Faron provides update at R&D day

Faron Pharmaceuticals will present an update on the company's pipeline activities around Traumakine and its novel cancer immunotherapy drug candidate Clevegen at its R&D Day in London. On 26 May the board of directors announced that the development
13-Jun-2016 07:21 AM

Faron licensing deal with Pharmbio

Faron Pharmaceuticals has entered into a licensing agreement with Pharmbio Korea Inc for the development and commercialisation of Traumakine in Korea. Pharmbio is based in Seoul and specialises in hospital sales of novel pharmaceutical products. Traum
13-May-2016 09:54 AM

Faron Pharmaceuticals to host an R&D Day

Faron Pharmaceuticals is hosting an R&D Day at Panmure Gordon's offices, One New Change, London, EC4M 9AF, on 14 June. The event will provide the opportunity to hear about the company, its pipeline and R&D strategy. At 9:54am: (LON:FARN) Faron
03-May-2016 07:44 AM

Faron appoints new medical director

Faron Pharmaceuticals has strengthened its executive management team with the appointment of Matti Karvonen as its new medical director. Dr. Karvonen will be responsible for overseeing Faron's drug development strategy and will play a central role
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t